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Introduction
Cystic fibrosis (CF) is one of the most common lifeshortening autosomal recessive diseases in Caucasians. The major cause of morbidity and mortality is progressive lung disease, characterized by a vicious circle of infection and inflammation [1] . The persistent inflammatory response in the airways is believed to play a central role in the progression of lung damage in CF [2] . Invariant natural killer T cells (iNK T cells), T helper type 2 (Th2) and Th17 T cells are likely to be involved in the chronic inflammation affecting CF lungs [3] [4] [5] . Anti-inflammatory treatment may slow lung disease progression, but adverse side effects have limited its use [6, 7] .
Vitamin D has a tolerogenic influence on dendritic cells (DCs) [8] . Vitamin D inhibits proliferation, maturation, survival and differentiation of DCs in vitro which, in turn, leads to decreased capacity to induce T cell activation [9, 10] . Simultaneously, it exerts a direct regulatory effect on T cells, inhibiting T cell proliferation and interleukin (IL)-17 and interferon (IFN)-g production [11] .
Vitamin D insufficiency occurs frequently in CF patients [12] . Current vitamin D supplementation recommendations for CF were designed with a focus on bone health and recommend vitamin D3 (D3) over vitamin D2 (D2) [13, 14] . However, a recent study has indicated that D2 may be as effective as D3 if given in a double dose [15] . In vitro studies have suggested that vitamin D may have beneficial immunomodulatory effects in CF [16, 17] . Adult CF patients admitted to hospital for pulmonary exacerbation and who received an oral bolus of 250 000 IU D3 showed reductions in serum IL-6 and tumour necrosis factor (TNF) levels [18] . Serum 25-hydroxyvitamin D (s25OHD) levels in CF patients have been associated independently with total serum immunoglobulin (Ig)G levels [12] , a marker of chronic inflammation [19] . It is currently discussed whether vitamin D treatment should be used as adjunctive immunoregulatory therapy in CF [20] .
Lipopolysaccharide (LPS) measured in plasma of CF patients is higher than in non-CF individuals and is believed to be derived from Pseudomonas aeruginosa or other Gram-negative bacteria [21] . Serum LPS levels are higher in patients who were hospitalized previously for a CF exacerbation than in those who were not [22] , and are associated positively with hospitalization rates in adult CF patients [23] . At the same time, CF monocytes stimulated ex vivo with LPS had lost the ability to up-regulate the triggering receptor expressed on myeloid cells-1 (TREM-1) [24] . In line with this, expression of TREM-1 on monocytes and the concentration of soluble TREM-1 (sTREM-1) in sera were shown to be pathologically low in CF. Interestingly, TREM-1 was induced by active vitamin D in airway epithelial cells [25] .
To our knowledge, the effect of vitamin D treatment on immunoglobulin concentrations, myeloid dendritic cells (mDCs) and T cell activation has not yet been evaluated in CF patients. The aim of this pilot trial was to investigate the effect of oral vitamin D supplementation on these parameters, using data collected in a previously published open-label pilot trial [26] .
Subjects and methods

Trial design
As described previously [26] , sixteen CF patients of age ! 6 years and with baseline total s25OHD (tot-s25OHD) < 75 nmol/l were randomized to receive D2, D3 or to serve as controls. Thirteen patients completed the study and were analysed. Clinical characteristics of patients completing the study were published previously [26] , and completing relevant information is listed in Table 1 . Three months of supplementation were followed by 2 months of washout. Patients below the age of 16 years randomized to the intervention arms received a starting weekly dose of 35 000 IU D2 or D3, whereas patients aged ! 16 years received a starting weekly dose of 50 000 IU D2 or D3. The weekly dose was given per os as seven once-daily doses, and adjusted by tot-s25OHD monitoring throughout the 3 months of intervention. The goal of the supplementation was to reach tot-s25OHD > 100 nmol/l [26] . There was no change in tot-s25OHD levels in the control group [26] . Patients receiving D2 had a tendency to increase tots25OHD, while patients supplemented with D3 increased tot-s25OHD levels significantly [26] .
The primary goal of the present study was to evaluate the effect of vitamin D treatment on soluble and cellular markers of immunological activation, and the secondary goal was to compare the effect of D2 with that of D3. Secondarily, we also aimed to investigate whether any effects of vitamin D were dose-dependent.
Analytical methods
Blood was sampled and analysed for erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), tot-s25OHD, albumin, vitamin D-binding protein (DBP), cytokines, acute phase proteins and immunoglobulins at baseline and at 1, 4, 8, 12, 16 and 20 weeks. At the last study visit patients reported their sun exposure throughout the study, which was quantified as described previously [26] . Serum albumin, calcium, ESR, CRP, anti-trypsin, orosomucoid, haptoglobin, TNF-a, IL-6, IgG, IgM, IgA, leucocytes, monocytes, eosinophils, lymphocytes, basophils and tots25OHD were analysed by standard methods at the Karolinska University Hospital Huddinge clinical laboratories. Plasma was collected and cryopreserved at 2808C. DBP assessed by exotoxin A antibodies, and/or ! 6 consecutive sputum cultures positive for Pseudomonas aeruginosa (with 1-month interval between the samples). ‡ Defined as ! 1 sputum culture positive for Pseudomonas aeruginosa, and < 6 consecutive sputum cultures positive for Pseudomonas aeruginosa within 6 months (with 1-month interval between the samples) and negative exotoxin A serology.
was measured as described previously [26] . . Free s25OHD (free-s25OHD) was calculated using tot-s25OHD, albumin and DBP, as described previously [26] . Peripheral blood mononuclear cells (PBMCs) were isolated by density-gradient sedimentation using FicollPaque (Lymphoprep, Axis-Shield) at baseline, end of intervention and end of the study. PBMCs were stored in liquid nitrogen. Specimens were thawed and washed, and cell counts and viability were assessed using the Muse count and viability kit (Merck Millipore) before flow cytometry analysis. Cells were washed and stained at room temperature for 10 min in 96-well V-bottomed plates in the dark. Samples were then washed and fixed using fixation solution (BD Biosciences, San Jose, CA, USA) before data acquisition. The monoclonal antibodies used in flow cytometry were the following: anti-CD3 AF700, anti-CD4 allophycocyanin (APC)-H7, anti-CD11c phycoerythrin-cyanin 5 (PE-Cy5), anti-CD38 PE-Cy7 
Statistical analysis
Statistical analyses were performed using STATISTICA version 10 and Prism version 6, and figures were created in Prism version 6. For each variable, we plotted raw data to assess normality of distribution. For comparisons within groups between two time-points, paired t-test (normally distributed data) or Wilcoxon's matched-pairs test (data without normal distribution) were used. For correlation analyses, Pearson's test or Spearman's test were used for normally or non-normally distributed data, respectively. For some statistical analyses, values were log-transformed (base e) if they were not distributed normally. Data were plotted as raw values. We considered P < 0Á05 as statistically significant.
Results
25OHD levels increase during intervention and decrease during the washout period
There were no statistically significant differences in the baseline demographics of the study groups, as reported previously [26] . The pooled group of patients receiving D2 or D3 increased their tot-s25OHD and free-s25OHD concentrations at the end of intervention. In this group, levels of both tot-s25OHD and free-s25OHD dropped significantly during the washout period ( Table 2 ). There were no reported symptoms of vitamin D toxicity, but there was a transitory increase in albumin-corrected plasma calcium in the D3 arm, compared with baseline (Supporting information, Fig. S1 ). The control group did not change their vitamin D status throughout the study (Table 2 ). There were no significant changes in any of the studied immunological parameters in the control group (Tables 2, 3 , Supporting information, Tables S1 and S2).
Haptoglobin correlates inversely with vitamin D status at baseline and change in vitamin D levels during treatment
Haptoglobin, orosomucoid and anti-trypsin are systemic markers of inflammation that are released in the acute phase of infection, and are increased in CF [27] . Reductions in haptoglobin are associated with improvements in lung function [28] and with the overall clinical improvement with antibiotic therapy [29] . The effect of vitamin D on acute phase proteins in CF has not yet been studied. In this pilot study, haptoglobin was correlated negatively with free-25OHD at baseline (Fig. 1a) . Changes in haptoglobin concentration were correlated negatively with changes in free-s25OHD at the end of intervention (Fig. 1b) and with changes in tot-s25OHD at the end of the study (Fig. 1c) . These observations suggest that s25OHD and haptoglobin levels are correlated inversely in CF.
LPS and sTREM-1 correlate with change in vitamin D levels during treatment
It was shown previously that CF monocytes stimulated ex vivo with LPS had lost the ability to up-regulate TREM-1 [24] , and sTREM-1 levels in sera were shown to be pathologically low in CF. Another study indicated that active vitamin D can induce TREM-1 in airway epithelial cells [25] . Therefore we studied effect of vitamin D treatment on sTREM and LPS levels. At the end of supplementation, change from baseline in tot-s25OHD was correlated negatively with change in LPS (Fig. 1d) , change in free-s25OHD correlated positively with change in plasma sTREM-1 and changes in sTREM-1 correlated with changes in LPS ( Fig. 1e and f) . At the same time-point, the change from baseline in free-s25OHD was correlated inversely with changes in monocyte count (Fig. 1g ). This suggests that vitamin D may influence the LPS-sTREM-1 axis in CF.
Vitamin D levels correlate with erythrocyte sedimentation rate and immunoglobulin concentrations
Erythrocyte sedimentation rate (ESR) is a marker of inflammation, which is determined largely by plasma fibrinogen and globulins, including immunoglobulins. IgG levels increase with age and are in CF correlated negatively with lung function [30] , as well as with exercise capacity and oxygen uptake [31] . In bronchial epithelial lining fluid, IgG, IgA and IgM concentrations are 2Á5-6 times greater in stable patients with mild CF compared with control subjects [32] . It is believed that the persistent inflammatory response in the airways plays a central role in the progression of lung damage in CF [2] . 1,25-dihydroxyvitamin D3 decreases B cell proliferation, plasma cell differentiation and immunoglobulin secretion [33, 34] . In light of this background, we investigated the effect of vitamin D treatment on ESR and immunoglobulin concentrations. At baseline, tot-s25OHD and frees25OHD were correlated negatively with ESR ( Fig. 2a,b) . At the end of supplementation, the change in ESR was correlated inversely with the change in tot-s25OHD from baseline ( Fig. 2c) . At baseline, tot-s25OHD and frees25OHD were correlated negatively with serum total IgA levels ( Fig. 3a,b) . At 1 week of supplementation, changes in free-s25OHD were correlated negatively with changes in serum total IgM (Fig. 3c) . D2, but not D3 (data not shown), supplementation tended to decrease serum total IgG concentration at 8 weeks of supplementation (P 5 0Á068; Supporting information, Fig. S2 ). Changes in free-s25OHD correlated with changes in plasma total IgE at 4 weeks of supplementation (Fig. 3d) . At the end of supplementation, there was an inverse correlation between both total vitamin D dose ingested and sun exposure and plasma total IgE (Fig. 3e,f) . Collectively, these (pg/ml) Total vitamin D dose per kg bodyweight correlates with the down-modulation of the co-stimulatory molecule CD86 on myeloid dendritic cells 1,25-dihydroxyvitamin D3 decreases differentiation, maturation and immunostimulatory capacity of DCs by inhibiting the expression of CD40, CD80, CD86 and major histocompatibility complex (MHC) class II molecules [35] [36] [37] [38] . Therefore, we hypothesized that vitamin D treatment would also decrease the expression of co-stimulatory molecules on mDCs in CF patients. mDCs were identified as described previously [39] . In line with this hypothesis, the total vitamin D dose per kg bodyweight correlated with the down-modulation of the co-stimulatory molecule CD86 on mDCs at the end of the study (Fig. 4) . This suggests that vitamin D is likely to inhibit the immunostimulatory capacity of DCs in CF in a dose-dependent manner.
Vitamin D treatment reduces CD279 (PD-1) expression on CD8
1 T cells as well as frequency of CD8 1 T cells co-expressing CD38 and HLA-DR
In the scenario of chronic T cell activation, vitamin D is believed to suppress T cell proliferation and cytokine production (as reviewed in [40] Haptoglobin was correlated negatively with free-s25OHD at baseline (a). Changes in haptoglobin concentration were correlated negatively with changes in free-s25OHD at the end of intervention (b), and with changes in tot-s25OHD at the end of the study (c). Change from baseline in tot-s25OHD versus change from baseline in plasma LPS levels at the end of supplementation in all patients (d). Change from baseline in frees25OHD versus change from baseline in plasma sTREM-1 levels at the end of supplementation in all patients (e). Change from baseline in LPS versus change from baseline in sTREM-1 at the end of supplementation in all patients (f). Change from baseline in free-s25OHD versus change from baseline in circulating monocyte count at the end of supplementation in all patients (g). P < 0Á05 in all. Results are plotted as raw data from all subjects participating in the study irrespective of treatment arm (a-g). The number of patients presented in the individual graphs varies due to a few missing samples (see Table 2 ).
reduced their HLA-DR and CD279 (PD-1) expression on CD8 1 T cells at the end of supplementation (Fig. 5a,b) . The frequency of CD8 1 T cells co-expressing CD38 and HLA-DR was also decreased at the end of supplementation (Fig. 5c ). The frequency of CD8 1 T cells expressing HLA-DR and co-expressing CD38 and HLA-DR increased significantly during the washout period, returning to baseline levels, while expression of CD279 (PD-1) by CD8
1 T cells remained down-regulated until the end of the study (Fig. 5a-c) . HLA-DR expression on CD8 1 T cells correlated with the total vitamin D dose per kg bodyweight at the end of intervention (Fig. 5d) , and the down-regulation of HLA-DR expression on CD8
1 T cells correlated with the change in tot-s25OHD at the end of the study (Fig. 5e) . Patients receiving D3, but not controls and patients receiving D2 (data not shown), displayed decreased CD279 Fig. 2 . Vitamin D levels correlate with erythrocyte sedimentation rate (ESR). Free serum 25-hydroxyvitamin D (free-s25OHD) was calculated and ESR was analysed as described in Subjects and methods. At baseline, tot-s25OHD (a) and free-s25OHD (b) were correlated negatively with ESR. At the end of supplementation, the change in ESR was correlated inversely with the change in tot-s25OHD from baseline (c). All Ps < 0Á05. Results are plotted as raw data from all subjects participating in the study irrespective of treatment arm (a-c). The number of patients presented in the individual graphs varies due to a few missing samples (see Table 2 ). Fig. 3 . Vitamin D levels correlate with immunoglobulin concentrations. Free serum 25-hydroxyvitamin D (free-s25OHD) was calculated and immunoglobulin (Ig)A, IgM, IgG and IgE were analysed as described in Subjects and methods. Sun exposure was quantified as described previously [26] . Total-s25OHD (a) and free-s25OHD (b) were correlated negatively with serum total IgA levels at baseline. Changes in frees25OHD were correlated negatively with changes in serum total IgM at 1 week of supplementation (c). Changes in free-s25OHD correlated with changes in plasma total IgE at 4 weeks of supplementation (d). At the end of supplementation, there was an inverse correlation between both sun exposure (e) and total vitamin D dose ingested (f) and plasma total IgE. P < 0Á05 in all, unless stated otherwise. Results are plotted as raw data from all subjects participating in the study irrespective of treatment arm (a-f). The number of patients presented in the individual graphs varies due to a few missing samples (see Table 2 ). 
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V
Vitamin D supplementation decreases the frequency of CD4 1 T cells expressing CD279 (PD-1) in a dose-dependent manner
At baseline, free-s25OHD was correlated negatively with the expression of HLA-DR by CD4
1 T cells and with the frequency of CD4 1 T cells co-expressing CD38 and HLA-DR (Fig. 6a,b) . The frequency of CD4 1 T cells coexpressing CD38 and HLA-DR was not affected by vitamin D supplementation (Supporting information, Fig. S3 ). At the end of the study, the combined group of patients receiving vitamin D2 or D3 experienced a decreased frequency of CD4 1 T cells expressing CD279 (PD-1) (Fig.   6c ). At this time-point, total vitamin D dose received was correlated negatively with change in CD279 (PD-1) expression by CD4 1 T cells (Fig. 6d ) and correlated positively with change in CD4/CD8 ratio (Fig. 6e) . This suggests that vitamin D treatment may ameliorate exhaustion of CD4
T cells in CF.
Trend towards decreased mucosal-associated invariant T cells (MAIT) cell frequency in patients receiving vitamin D and free-s25OHD correlates positively with CD38 expression by these cells
MAIT cells are believed to contribute to protection from pulmonary infections [41, 42] , and reduced MAIT cell frequency in peripheral blood is associated with more severe lung disease in CF [43] . In asthma patients, MAIT cell frequencies correlate with vitamin D levels [44] . Therefore we asked whether there is any association between vitamin D and MAIT cells in CF patients. At baseline, free-s25OHD was correlated positively with CD38 expression and tended to correlate with HLA-DR expression by MAIT cells (Fig.  7a,b) . MAIT cells were identified by the co-expression of CD161 and Va7Á2 in T cells (Fig. 7c ). There was a trend towards decreased MAIT cell frequency at the end of intervention compared with baseline in the combined group of patients receiving vitamin D2 or D3 (P 5 0Á0506; Fig.  7c,d) . At the end of intervention, the change in frees25OHD was correlated negatively with the change in CD279 (PD-1) expression on MAIT cells (Fig. 7e) . Jointly, these observations indicate that vitamin D may influence MAIT cells' activation state as well as their frequency in peripheral blood in CF. By influencing pulmonary macrophages, iNK T cells can improve the course of P. aeruginosa or Mycobacterium tuberculosis pneumonia infection [45, 46] . The vitamin D receptor is required for iNK T cell development in mice [47] , but low iNK T cell numbers could not be corrected by later intervention with vitamin D in a mouse model [48] . In line with this, the frequency of iNK T cells (Va24 
Discussion
This pilot study supports the notion that high-dose oncedaily vitamin D supplementation may decrease immune activation in CF in a dose-dependent manner. For several of the parameters that were affected by vitamin D supplementation there was also an association with the change in the level of tot-or free-s25OHD, reinforcing the biological relevance of our findings.
In this trial, vitamin D treatment had a much more profound effect on CD8
1 T cells compared with CD4 1 T cells (Figs 5 and 6) . Similarly, the vitamin D analogue calcipotriol was reported previously to reduce the frequency of IL17
1
CD8
1 T cells in psoriasis, while leaving the CD4 1 T cells unaffected [49] . In experimental inflammatory bowel disease, VDR expression was required to prevent replication of quiescent CD8 1 T cells [50] . One may speculate that vitamin D targets CD8
1 T cells directly in CF, reducing their activation, while its effect on CD4 1 T cells may be more indirect or mediated through different pathways.
We have described previously a negative association between serum total IgG levels and vitamin D status in a large cohort of Scandinavian CF patients [12] . In this cohort, D2 supplementation was associated more closely with alterations in IgG levels compared with D3 supplementation (unpublished observations). Those observations are in line with the results of the present pilot trial, where D2 but not D3 supplementation tended to decrease IgG (Supporting information, Fig. S2) . Conversely, the vast majority of significant immunological changes in this trial Results are plotted as raw data from all subjects participating in the study irrespective of treatment arm. The number of observations presented in the graph is smaller than the total number of patients due to a few missing samples (see Table 3 ).
were observed in the combined group of patients receiving D2 or D3. We speculate that D2 and D3 may both have some immunomodulatory effects, possibly affecting different pathways with different magnitude, which would speak in favour of using a combination supplement. In this pilot trial the average D2 daily dose was almost double the D3 dose, due to the lower efficacy of D2 at increasing s25OHD concentration [26] . Local immunomodulatory effects of vitamin D in the gut are well documented [51] , and may partially explain the difference between the effect of D2 and D3 on IgG levels. Taken together, our results generate a hypothesis that D2 exerts some immunomodulatory effect when given in high doses despite being less efficient at improving vitamin D status. Larger studies are needed to test this hypothesis. Conversely, only patients receiving D3 and not patients receiving D2 displayed decreased PD-1 expression on CD8 T cells (Fig. 5f ). We speculate that this might be explained by the fact that D2 supplementation was less efficient at increasing s25OHD, as only patients supplemented with D3 increased tot-s25OHD levels significantly [26] .
In a recent trial by Simoneau [15] there was a trend towards a reduction in IgE in CF patients receiving a weekly dose 50 000 IU D3, and low s25OHD has been shown to be associated with high IgE concentrations [52] . This is in line with the results of this pilot trial, where we observed a negative correlation between changes in IgE and changes in free-s25OHD (Fig. 3d) , as well as between vitamin D doses and IgE (Fig. 3f) . These findings suggest that vitamin D treatment may have a dose-dependent negative effect on plasma total IgE levels. Future studies are needed to confirm this in a larger CF population, as well as to determine the clinical relevance of these findings. and vitamin D3 treatment group (a-c), raw data from all subjects participating in the study irrespective of treatment arm (d,e) and as raw data from subjects in the vitamin D3 treatment group (f). The number of patients presented in the individual graphs varies due to a few missing samples (see Table 3 ).
Vitamin D and immune activation in CF In this pilot study, changes in s25OHD were associated negatively with changes in plasma LPS and positively with changes in sTREM-1. Several in-vitro and mouse studies have shown that vitamin D receptor signalling is crucial for mucosal barrier homeostasis [53] [54] [55] . Moreover, active vitamin D abrogated the destructive effect of LPS on monolayer permeability by restoring tight junction proteins [56] and prevented airway epithelial barrier disruption [57] . In light of this background, we speculate that vitamin D treatment in this study may have strengthened the airway epithelial barrier, thus decreasing LPS translocation from the lungs, which enabled TREM-1 up-regulation.
There are indications in the literature that there might be an association between vitamin D and MAIT cells [44] , but this has not been investigated in more detail. In this trial, patients randomized to receive D2 or D3 vitamin tended to display decreased MAIT cell frequency at the end of intervention (Fig. 7c,d) , and the change in free-s25OHD was correlated negatively with the change in CD279 (PD-1) expression on MAIT cells (Fig. 7e) . We speculate that vitamin D treatment might enhance migration of activated MAIT cells to the lungs, decreasing their numbers as well as their exhaustion markers in the circulation.
Some of the immunological changes that were observed following vitamin D treatment were short-lived, returning to baseline levels during the washout period. This was evident for the frequency of CD8 1 T cells co-expressing CD38 and HLA-DR (Fig. 5c) , as well as the total frequency of HLA-DR 1 CD8 T cells (Fig. 5a) . Conversely, other parameters, such as CD279 (PD-1) expression on CD8 1 T cells (Fig. 5b) or IL-8 [26] , remained down-regulated throughout the washout period, despite the fact that vitamin D levels dropped during washout. This underscores that vitamin D has pleiotropic effects affecting numerous arms of the Results are plotted as raw data from all subjects participating in the study irrespective of treatment arm (a,b,d,e) and as raw data from the subjects in the pooled vitamin D2 and vitamin D3 treatment group (c). The number of patients presented in the individual graphs varies due to a few missing samples (see Table 3 ).
immune system and that its impact on these arms may be short or sustained for longer time-periods. In summary, this pilot trial indicates that vitamin D supplementation may modulate immune activation in CF in a complex manner. It also suggests that vitamin D2 may be a non-inferior substitute for the currently recommended vitamin D3, if given in higher doses. This study has generated novel observations that need to be follow-up in larger long-term placebo-controlled studies. There was a trend towards decreased MAIT cell frequency at the end of intervention compared with baseline in the combined group of patients receiving vitamin D2 or D3, P 5 0Á0506 (d). At the end of intervention, the change in free-s25OHD was correlated negatively with the change in CD279 (programmed death 1) expression on MAIT cells (e). P < 0Á05 in all, unless stated otherwise. Results are plotted as raw data from all subjects participating in the study irrespective of treatment arm (a,b,e) and as raw data from the subjects in the pooled vitamin D2 and vitamin D3 treatment group (d). The number of patients presented in the individual graphs varies due to a few missing samples (see Table 3 ). 
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Supporting information
Additional Supporting information may be found in the online version of this article at the publisher's web-site: Fig. S1 . Albumin-corrected plasma calcium concentration increased at 1 week of supplementation and at the end of the study in the vitamin D3 group (P < 0Á05). 
